These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 28703802

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.
    Singh JK, Farnie G, Bundred NJ, Simões BM, Shergill A, Landberg G, Howell SJ, Clarke RB.
    Clin Cancer Res; 2013 Feb 01; 19(3):643-56. PubMed ID: 23149820
    [Abstract] [Full Text] [Related]

  • 5. ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel.
    Mao J, Song B, Shi Y, Wang B, Fan S, Yu X, Tang J, Li L.
    Int J Biochem Cell Biol; 2013 Jun 01; 45(6):1064-73. PubMed ID: 23500524
    [Abstract] [Full Text] [Related]

  • 6. Autocrine control of MIP-2 secretion from metastatic breast cancer cells is mediated by CXCR2: a mechanism for possible resistance to CXCR2 antagonists.
    Erin N, Nizam E, Tanrıöver G, Köksoy S.
    Breast Cancer Res Treat; 2015 Feb 01; 150(1):57-69. PubMed ID: 25682075
    [Abstract] [Full Text] [Related]

  • 7. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
    Goldstein LJ, Perez RP, Yardley D, Han LK, Reuben JM, Gao H, McCanna S, Butler B, Ruffini PA, Liu Y, Rosato RR, Chang JC.
    Breast Cancer Res; 2020 Jan 10; 22(1):4. PubMed ID: 31924241
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Multiple anti-tumor effects of Reparixin on thyroid cancer.
    Liotti F, De Pizzol M, Allegretti M, Prevete N, Melillo RM.
    Oncotarget; 2017 May 30; 8(22):35946-35961. PubMed ID: 28415590
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-8, but not the Related Chemokine CXCL1, Sustains an Autocrine Circuit Necessary for the Properties and Functions of Thyroid Cancer Stem Cells.
    Liotti F, Collina F, Pone E, La Sala L, Franco R, Prevete N, Melillo RM.
    Stem Cells; 2017 Jan 30; 35(1):135-146. PubMed ID: 27577959
    [Abstract] [Full Text] [Related]

  • 11. β-Catenin and NF-κB co-activation triggered by TLR3 stimulation facilitates stem cell-like phenotypes in breast cancer.
    Jia D, Yang W, Li L, Liu H, Tan Y, Ooi S, Chi L, Filion LG, Figeys D, Wang L.
    Cell Death Differ; 2015 Feb 30; 22(2):298-310. PubMed ID: 25257174
    [Abstract] [Full Text] [Related]

  • 12. Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-κB-TNFα-PIK3CA loop.
    Thakur B, Ray P.
    J Exp Clin Cancer Res; 2017 Nov 23; 36(1):164. PubMed ID: 29169370
    [Abstract] [Full Text] [Related]

  • 13. CXCR1/2 pathways in paclitaxel-induced neuropathic pain.
    Brandolini L, Benedetti E, Ruffini PA, Russo R, Cristiano L, Antonosante A, d'Angelo M, Castelli V, Giordano A, Allegretti M, Cimini A.
    Oncotarget; 2017 Apr 04; 8(14):23188-23201. PubMed ID: 28423567
    [Abstract] [Full Text] [Related]

  • 14. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
    Liu X, Peng J, Sun W, Yang S, Deng G, Li F, Cheng JW, Gordon JR.
    Tohoku J Exp Med; 2012 Oct 04; 228(2):147-56. PubMed ID: 23019013
    [Abstract] [Full Text] [Related]

  • 15. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
    Al-Dhfyan A, Alhoshani A, Korashy HM.
    Mol Cancer; 2017 Jan 19; 16(1):14. PubMed ID: 28103884
    [Abstract] [Full Text] [Related]

  • 16. Induction of CXCR2 ligands, stem cell-like phenotype, and metastasis in chemotherapy-resistant breast cancer cells.
    Sharma B, Varney ML, Saxena S, Wu L, Singh RK.
    Cancer Lett; 2016 Mar 28; 372(2):192-200. PubMed ID: 26797460
    [Abstract] [Full Text] [Related]

  • 17. Caveolin-1 mediates chemoresistance in breast cancer stem cells via β-catenin/ABCG2 signaling pathway.
    Wang Z, Wang N, Li W, Liu P, Chen Q, Situ H, Zhong S, Guo L, Lin Y, Shen J, Chen J.
    Carcinogenesis; 2014 Oct 28; 35(10):2346-56. PubMed ID: 25085904
    [Abstract] [Full Text] [Related]

  • 18. HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells.
    Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, Pettigrew J, Stratford IJ, Williams KJ, Johnston PG, Waugh DJ.
    Oncogene; 2007 Nov 15; 26(52):7333-45. PubMed ID: 17533374
    [Abstract] [Full Text] [Related]

  • 19. The novel inhibitor BRM270 downregulates tumorigenesis by suppression of NF-κB signaling cascade in MDR-induced stem like cancer-initiating cells.
    Mongre RK, Sodhi SS, Ghosh M, Kim JH, Kim N, Park YH, Kim SJ, Heo YJ, Sharma N, Jeong DK.
    Int J Oncol; 2015 Nov 15; 46(6):2573-85. PubMed ID: 25872586
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of interleukin 8/C‑X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells.
    Fu S, Chen X, Lin HJ, Lin J.
    Int J Oncol; 2018 Jul 15; 53(1):349-357. PubMed ID: 29749433
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.